Cetuximab for patients with metastatic colorectal cancer - From the result of recent clinical trials

Research output: Contribution to journalArticle

Abstract

Cetuximab is a monoclonal antibody that inhibits human epidermal growth factor receptor, and was approved for metastatic advanced colorectal cancer (mCRC) in 2008 in Japan. Evidences confirming the efficacy of cetuximab have been accumulated in western countries. As the first- and second-line therapy, cetuximab plus chemotherapy showed longer survival compared with chemotherapy alone. As a third-line chemotherapy, among various anti-cancer agents for mCRC, only cetuximab could exhibit survival benefits in monotherapy or combination therapy with irinotecan. Recent studies suggest that the status of KRAS mutation is a predictive marker in colorectal cancer patients treated with cetuximab, and these findings lead to personalized cancer treatment.

Original languageEnglish
Pages (from-to)782-786
Number of pages5
JournalJapanese Journal of Cancer and Chemotherapy
Volume37
Issue number5
Publication statusPublished - 2010

Fingerprint

Colorectal Neoplasms
Clinical Trials
irinotecan
Drug Therapy
Survival
Epidermal Growth Factor Receptor
Neoplasms
Japan
Therapeutics
Monoclonal Antibodies
Cetuximab
Mutation

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

@article{16c2395cc8d14727907d0382ce95dc2c,
title = "Cetuximab for patients with metastatic colorectal cancer - From the result of recent clinical trials",
abstract = "Cetuximab is a monoclonal antibody that inhibits human epidermal growth factor receptor, and was approved for metastatic advanced colorectal cancer (mCRC) in 2008 in Japan. Evidences confirming the efficacy of cetuximab have been accumulated in western countries. As the first- and second-line therapy, cetuximab plus chemotherapy showed longer survival compared with chemotherapy alone. As a third-line chemotherapy, among various anti-cancer agents for mCRC, only cetuximab could exhibit survival benefits in monotherapy or combination therapy with irinotecan. Recent studies suggest that the status of KRAS mutation is a predictive marker in colorectal cancer patients treated with cetuximab, and these findings lead to personalized cancer treatment.",
author = "hiroshi ariyama and Hitoshi Kusaba and Eishi Baba",
year = "2010",
language = "English",
volume = "37",
pages = "782--786",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "5",

}

TY - JOUR

T1 - Cetuximab for patients with metastatic colorectal cancer - From the result of recent clinical trials

AU - ariyama, hiroshi

AU - Kusaba, Hitoshi

AU - Baba, Eishi

PY - 2010

Y1 - 2010

N2 - Cetuximab is a monoclonal antibody that inhibits human epidermal growth factor receptor, and was approved for metastatic advanced colorectal cancer (mCRC) in 2008 in Japan. Evidences confirming the efficacy of cetuximab have been accumulated in western countries. As the first- and second-line therapy, cetuximab plus chemotherapy showed longer survival compared with chemotherapy alone. As a third-line chemotherapy, among various anti-cancer agents for mCRC, only cetuximab could exhibit survival benefits in monotherapy or combination therapy with irinotecan. Recent studies suggest that the status of KRAS mutation is a predictive marker in colorectal cancer patients treated with cetuximab, and these findings lead to personalized cancer treatment.

AB - Cetuximab is a monoclonal antibody that inhibits human epidermal growth factor receptor, and was approved for metastatic advanced colorectal cancer (mCRC) in 2008 in Japan. Evidences confirming the efficacy of cetuximab have been accumulated in western countries. As the first- and second-line therapy, cetuximab plus chemotherapy showed longer survival compared with chemotherapy alone. As a third-line chemotherapy, among various anti-cancer agents for mCRC, only cetuximab could exhibit survival benefits in monotherapy or combination therapy with irinotecan. Recent studies suggest that the status of KRAS mutation is a predictive marker in colorectal cancer patients treated with cetuximab, and these findings lead to personalized cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=79960766401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960766401&partnerID=8YFLogxK

M3 - Article

VL - 37

SP - 782

EP - 786

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 5

ER -